Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Archives of pharmacal research

• Publication date

  2015-05-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12272-015-0592-9PMID 25956695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative determination of enzalutamide, an anti-prostate cancer drug, in rat plasma using liquid chromatography-tandem mass spectrometry, and its application to a pharmacokinetic study.

  2014cited by this paper
• 2012 FDA drug approvals

  2013cited by this paper
• Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer

  2013cited by this paper
• Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

  2013cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Comprar Physiologically Based Pharmacokinetic (PBPK) Modeling And Simulations. Principles, Methods, And Applications In The Pharmaceutical Industry | Sheila Annie Peters | 9780470484067 | Wiley

  2012cited by this paper
• Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry

  2012cited by this paper
• Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats

  2011cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection.

  2007cited by this paper
• Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

  2006cited by this paper
• LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.

  1997cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

  1977cited by this paper

• Behavioral Alterations in Male Zebrafish After Administration of Androgen Receptor Blockers and an Activator

  2026cites this paper
• A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

  2025influential citation
• Daidzein-engineered high-accumulation self-therapeutic nanoplatform drives androgen receptor degradation via ubiquitination-proteasome system to overcome enzalutamide resistance in castration-resistant prostate cancer

  2025influential citation
• Preclinical Development of GT-14, a Novel Inhibitor of Gαi2 Protein: Comprehensive Evaluation of Physicochemical, Metabolic Characteristics and Tissue Distribution

  2025cites this paper
• Preclinical Pharmacokinetics of DM5167, a Novel Selective PARP1 Inhibitor

  2025influential citation
• The Impact of Polymers on Enzalutamide Solid Self-Nanoemulsifying Drug Delivery System and Improved Bioavailability

  2024influential citation
• Androgen receptor inhibitors in treating prostate cancer

  2024cites this paper
• Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics

  2024cites this paper
• DoE-assisted HPLC method development and validation of enzalutamide and repaglinide in rat plasma.

  2024cites this paper
• Enhanced Stability and Improved Oral Absorption of Enzalutamide with Self-Nanoemulsifying Drug Delivery System

  2024cites this paper
• Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives.

  2023cites this paper
• Late-Stage Diversification of Peptides via Pd-Catalyzed Site-Selective δ-C(sp2)-H Fluorination and Amination.

  2023cites this paper
• AR independent anticancer potential of Enza against prostate cancer

  2022cites this paper
• Cocrystal and Coamorphous Solid Forms of Enzalutamide with Saccharin: Structural Characterization and Dissolution Studies

  2022cites this paper
• Nuclear Receptor Imaging In Vivo—Clinical and Research Advances

  2022cites this paper
• Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.

  2021cites this paper
• Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer

  2021cites this paper
• Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone

  2021cites this paper
• Sulfur-containing natural hinduchelins derivatives as potential antifungal agents against Rhizoctonia solani.

  2020cites this paper
• Synthesis and biological activities of novel trifluoromethylpyridine amide derivatives containing sulfur moieties

  2020cites this paper
• Selective Methylation of Amides, N-Heterocycles, Thiols, and Alcohols with Tetramethylammonium Fluoride.

  2019cites this paper
• Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

  2019cites this paper
• A Validated Stability Indicating RP-HPLC Method Development for Anticancer Drug Enzalutamide in Bulk and Pharmaceuticals

  2019cites this paper
• Analysis of US FDA-Approved Drugs Containing Sulfur Atoms

  2018cites this paper
• Chromatographic Methods for Determination of Drugs Used in Prostate Cancer in Biological and Pharmacological Samples

  2018cites this paper
• Nitrate-promoted Selective C-H Fluorination of Benzamides and Benzeneacetamides.

  2018cites this paper
• Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats

  2018cites this paper
• Dose considerations for anti‐cancer drugs in metastatic prostate cancer

  2017cites this paper
• Convenient Structural Diversity‐Guided Synthesis of Functionalized Sulfur‐Containing Heterocycles via α‐Substituted Cyanoacetamides

  2017cites this paper
• Quality by Design–Applied Liquid Chromatography-Tandem Mass Spectrometry Determination of Enzalutamide Anti-Prostate Cancer Therapy Drug in Spiked Plasma Samples

  2017cites this paper